Covid-19 Vaccine and Antiviral Development
We are ready to answer your questions and provide guidance.
covid-19 Vaccine anD
IITRI is in custody of the SARS-CoV-2 strain responsible for Covid-19. If your team is interested in testing your target antiviral/antagonist against the virus, we offer in vitro assays in BSL-3 containment to determine efficacy (cell survival endpoints being EC50 and TC50).
Our team is also characterizing the strain for in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this coronavirus.
IITRI provides IND-enabling vaccine programs, with over 30 years of experience conducting GLP-compliant toxicology studies. We support vaccine basic research through FDA approval programs for sponsors from government, biotech, academic, and pharma institutions.